PALO ALTO, Calif. and NASHVILLE, Tenn., April 30, 2015 /PRNewswire/ --Varian Medical Systems (NYSE:VAR) and Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), today announced a new initiative to upgrade the radiation oncology equipment across the Sarah Cannon Cancer Network of Excellence with newly advanced technology for image-guided, high-precision radiotherapy and radiosurgery. Sarah Cannon will also deploy Varian's new InSightive™ software for data analytics and RapidPlan™ knowledge-based treatment planning software together with Varian's ARIA® information management and Eclipse™ treatment planning software. The software will support Sarah Cannon's programs for using data to develop personalized treatment plans, improve outcomes, and expand clinical trial options for patients.
The project is part of a long-term plan for enhancing and expanding radiotherapy and radiosurgery cancer treatment capabilities across the Sarah Cannon Cancer Network of Excellence. Sarah Cannon has access to more than 100,000 newly-diagnosed cancer patients per year and offers integrated cancer services with convenient access to cutting-edge therapies through its network of cancer programs across the United States and United Kingdom.
"Sarah Cannon believes that no one initiative or technology creates a superior radiation oncology offering and that it takes a comprehensive approach to interconnect and support the entire program," said Andrew Kennedy, MD, physician in chief, Radiation Oncology for Sarah Cannon. "The InSightive software and RapidPlan knowledge-based treatment planning will enable us to better serve our patients across the network."
Over the next 18 months Sarah Cannon will install six Varian TrueBeam™ systems for image-guided radiotherapy and radiosurgery, as well as a Clinac® machine for image-guided intensity-modulated radiation therapy (IMRT), a highly precise method of focusing radiation on a tumor while minimizing exposure of surrounding healthy tissues and organs. The new TrueBeam systems will enable Sarah Cannon increased levels of versatility, efficiency, reliability, and a lower cost per patient in offering advanced treatments like stereotactic radiosurgery.
"The InSightive software offers us an interactive dashboard for capturing, organizing, and visualizing data from our clinical and administrative operations in radiation oncology," said Kennedy. "The goal is to identify patterns in patient data that support the development of personalized treatment plans for patients, and ultimately to improve treatment outcomes."
Varian booked the Sarah Cannon order during its fiscal second quarter and will book revenues in accordance with the company's policies over the term of the agreement.
"We are excited and honored to collaborate with Sarah Cannon, a leader in cancer care and research, as they work to bring world-class care to those facing cancer in the community," said Chris Toth, Varian's president, Oncology Systems Americas. "At Varian, we have a vision of a world without fear of cancer, and of helping to save millions of lives around the world every year. This collaboration brings us another step closer to realizing these goals."
About Varian Medical Systems Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
About Sarah Cannon Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon's cancer programs address every aspect of cancer care from diagnosis through survivorship, including individualized patient navigation provided by oncology-trained nurses, more than 900 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, as well as access to more than 500 clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
Forward-Looking Statements Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues or other financial performance; the ability of the company's technology and products to treat cancer; and any statements using the terms "will deploy," "long-term plan," "are envisioned," "will enable," "will acquire," "will replace," "offers," and "will book," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.